HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS Marketplace In Brief

This article was originally published in The Rose Sheet

Executive Summary

Clearasil: Clearasil Ultra line will be extended with Acne Scar Care System, a regimen "specially formulated to reduce the appearance of scars leftover from acne and help prevent new ones from forming," according to Boots Healthcare International. The range was presented at the National Association of Chain Drug Stores Marketplace conference in New Orleans June 4-7. Targeted to consumers ages 18-24, line features three products, including Exfoliating Acne Wash, which contains 2% salicylic acid and a dual exfoliator that "stimulates skin renewal." Protecting Day Lotion with SPF 15 "protects healing skin" and contains 7.5% octinoxate and 2.5% avobenzone, while Night Repair Lotion "improves the appearance of scars." System, which provides 30-45 days of treatment, will carry an SRP of $19.99-$24.99. Acne Scar Care System will launch in the U.S. in July and will be supported with national print ads...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel